212 related articles for article (PubMed ID: 35595746)
1. Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues.
Bo Q; Yang F; Li Y; Meng X; Zhang H; Zhou Y; Ling S; Sun D; Lv P; Liu L; Shi P; Tian C
Cell Discov; 2022 May; 8(1):47. PubMed ID: 35595746
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin and its receptor family.
Patel YC
Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
4. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
Raynor K; Murphy WA; Coy DH; Taylor JE; Moreau JP; Yasuda K; Bell GI; Reisine T
Mol Pharmacol; 1993 Jun; 43(6):838-44. PubMed ID: 8100350
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into ligand recognition and selectivity of somatostatin receptors.
Zhao W; Han S; Qiu N; Feng W; Lu M; Zhang W; Wang M; Zhou Q; Chen S; Xu W; Du J; Chu X; Yi C; Dai A; Hu L; Shen MY; Sun Y; Zhang Q; Ma Y; Zhong W; Yang D; Wang MW; Wu B; Zhao Q
Cell Res; 2022 Aug; 32(8):761-772. PubMed ID: 35739238
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors and disease: role of receptor subtypes.
Hofland LJ; Lamberts SW
Baillieres Clin Endocrinol Metab; 1996 Jan; 10(1):163-76. PubMed ID: 8734455
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogues and multiple receptors: possible physiological roles.
Coy DH; Rossowski WJ
Ciba Found Symp; 1995; 190():240-52; discussion 252-4. PubMed ID: 7587650
[TBL] [Abstract][Full Text] [Related]
9. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.
Kumar U; Sasi R; Suresh S; Patel A; Thangaraju M; Metrakos P; Patel SC; Patel YC
Diabetes; 1999 Jan; 48(1):77-85. PubMed ID: 9892225
[TBL] [Abstract][Full Text] [Related]
10. The role of somatostatin receptors in the medical treatment of acromegaly.
Vitale G; Pivonello R; Ferone D; De Martino MC; Auriemma RS; Caraglia M; Abbruzzese A; Lombardi G; Colao A
Dig Liver Dis; 2004 Feb; 36 Suppl 1():S55-9. PubMed ID: 15077912
[TBL] [Abstract][Full Text] [Related]
11. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
12. Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand-binding specificity.
Heo Y; Yoon E; Jeon YE; Yun JH; Ishimoto N; Woo H; Park SY; Song JJ; Lee W
Elife; 2022 Apr; 11():. PubMed ID: 35446253
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
Shimon I
Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
[TBL] [Abstract][Full Text] [Related]
14. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
Wahid ST; Marbach P; Stolz B; Miller M; James RA; Ball SG
Eur J Endocrinol; 2002 Mar; 146(3):295-302. PubMed ID: 11888834
[TBL] [Abstract][Full Text] [Related]
15. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for activation of somatostatin receptor 5 by cyclic neuropeptide agonists.
Li J; You C; Li Y; Li C; Fan W; Chen Z; Hu W; Wu K; Xu HE; Zhao LH
Proc Natl Acad Sci U S A; 2024 Jun; 121(26):e2321710121. PubMed ID: 38885377
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin and its Analogs.
Sun L; Coy DH
Curr Drug Targets; 2016; 17(5):529-37. PubMed ID: 26951062
[TBL] [Abstract][Full Text] [Related]
18. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.
Kailey B; van de Bunt M; Cheley S; Johnson PR; MacDonald PE; Gloyn AL; Rorsman P; Braun M
Am J Physiol Endocrinol Metab; 2012 Nov; 303(9):E1107-16. PubMed ID: 22932785
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells.
Oomen SP; van Hennik PB; Antonissen C; Lichtenauer-Kaligis EG; Hofland LJ; Lamberts SW; Löwenberg B; Touw IP
Exp Hematol; 2002 Feb; 30(2):116-25. PubMed ID: 11823046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
